Search

Displaying results 2991 - 3000 of 4300 in total
  1. Drug

    Leptin

    go.drugbank.com/drugs/DB05098
    Investigational

    Thus, obesity develops when people take in more energy than they use over a prolonged period of time, and this excess food intake is not driven by hunger signals, occurring in spite of the anti-appetite

  2. Drug

    XEN-2174

    go.drugbank.com/drugs/DB05012
    Experimental

    In episodes of pain, inhibition of NET by XEN-2174 elevates the levels of NE leading to the activation of inhibitory pathways preventing pain signals from reaching the brain.

  3. Drug

    Agomelatine

    go.drugbank.com/drugs/DB06594
    ApprovedInvestigational

    Agomelatine was developed in Europe by Servier Laboratories Ltd. and submitted to the European Medicines Agency (EMA) in 2005.

  4. Drug

    Tarlatamab

    go.drugbank.com/drugs/DB17256
    ApprovedInvestigational

    [L50743] Tarlatamab-dlle was approved by the FDA in May 2024 for use in patients who have failed previous round of platinum-based chemotherapy,[L50743,L50748] becoming the first DLL3-targeting bispecific

  5. Drug

    S-40503

    go.drugbank.com/drugs/DB13938
    Experimental

    S-40503 is an investigational selective androgen receptor modulator (SARM) developed for the treatment of osteoporosis by the Japanese company Kaken Pharmaceuticals.

  6. Drug

    AAV-dXIAP

    go.drugbank.com/drugs/DB17880
    Experimental

    AAV-dXIAP is a recombinant adeno-associated virus-encoded gene for X-linked mammalian inhibitor of apoptosis protein (XIAP) developed by Neurologix.

  7. Drug

    Alintegimod

    go.drugbank.com/drugs/DB18879
    Investigational

    Alintegimod is under investigation in clinical trial NCT06362369 (A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy).

  8. Drug

    Adenosine 5'-[gamma-thio]triphosphate

    go.drugbank.com/drugs/DB02930
    Experimental

    A nucleoside triphosphate analogue that is ATP in which one of the oxygens attached to 3-phosphate group is replaced by sulfur.

  9. Drug

    Mitoquinone

    go.drugbank.com/drugs/DB05063
    Investigational

    Clinical studies by the Parkinson's Study Group show that very high doses of an antioxidant called Coenzyme Q (which Mitoquinone effectively targets into mitochondria) appear to slow the progression of

  10. Drug

    Brifentanil

    go.drugbank.com/drugs/DB09172
    ExperimentalIllicit

    The effects of brifentanil are very similar to those of alfentanil, with strong but short lasting analgesia and sedation, and particularly notable itching and respiratory depression.